Abstract/JJ The/DT canine/JJ parvovirus/NN NS1/NN -LRB-/-LRB- CPV2.NS1/NN -RRB-/-RRB- protein/NN selectively/RB induces/VBZ apoptosis/NN in/IN the/DT malignant/JJ cells/NNS ./.However/RB ,/, for/IN an/DT effective/JJ in/FW vivo/FW tumor/NN treatment/NN strategy/NN ,/, an/DT oncolytic/JJ agent/NN also/RB needs/VBZ to/TO induce/VB a/DT potent/JJ anti-tumor/JJ immune/JJ response/NN ./.In/IN the/DT present/JJ study/NN ,/, we/PRP used/VBD poly/NN -LRB-/-LRB- I/PRP :/: C/NN -RRB-/-RRB- ,/, a/DT TLR3/NN ligand/NN ,/, as/IN an/DT adjuvant/JJ along/IN with/IN CPV2.NS1/NN to/TO find/VB out/RP if/IN the/DT combination/NN can/MD enhance/VB the/DT oncolytic/JJ activity/NN by/IN inducing/VBG a/DT potent/JJ anti-tumor/JJ immune/JJ response/NN ./.The/DT 4T1/NN mammary/JJ carcinoma/NN cells/NNS were/VBD used/VBN to/TO induce/VB mammary/JJ tumor/NN in/IN Balb/c/NN mice/NNS ./.The/DT results/NNS suggested/VBD that/IN poly/NN -LRB-/-LRB- I/PRP :/: C/NN -RRB-/-RRB- ,/, when/WRB given/VBN along/RP with/IN CPV2.NS1/NN ,/, not/RB only/RB significantly/RB reduced/VBD the/DT tumor/NN growth/NN but/CC also/RB augmented/VBD the/DT immune/JJ response/NN against/IN tumor/NN antigen/NN -LRB-/-LRB- s/NNS -RRB-/-RRB- as/IN indicated/VBN by/IN the/DT increase/NN in/IN blood/NN CD4/NN +/CC and/CC CD8/NN +/CC counts/NNS and/CC infiltration/NN of/IN immune/JJ cells/NNS in/IN the/DT tumor/NN tissue/NN ./.Further/RB ,/, blood/NN serum/NN analysis/NN of/IN the/DT cytokines/NNS revealed/VBD that/IN Th1/NN cytokines/NNS -LRB-/-LRB- IFN-Î/NN ³/NN and/CC IL-2/NN -RRB-/-RRB- were/VBD significantly/RB upregulated/VBN in/IN the/DT treatment/NN group/NN indicating/VBG activation/NN of/IN cell-mediated/JJ immune/JJ response/NN ./.The/DT present/JJ study/NN reports/VBZ the/DT efficacy/NN of/IN CPV2.NS1/NN along/IN with/IN poly/NN -LRB-/-LRB- I/PRP :/: C/NN -RRB-/-RRB- not/RB only/RB in/IN inhibiting/VBG the/DT mammary/JJ tumor/NN growth/NN but/CC also/RB in/IN generating/VBG an/DT active/JJ anti-tumor/JJ immune/JJ response/NN without/IN any/DT visible/JJ toxicity/NN ./.The/DT results/NNS of/IN our/PRP$ study/NN may/MD help/VB in/IN developing/VBG CPV2.NS1/NN and/CC poly/NN -LRB-/-LRB- I/PRP :/: C/NN -RRB-/-RRB- combination/NN as/IN a/DT cancer/NN therapeutic/JJ regime/NN to/TO treat/VB various/JJ malignancies/NNS ./.KEYWORDS/NNS :/: Anti-tumor/JJ immune/JJ response/NN ;/: Apoptosis/NN ;/: Breast/NN cancer/NN ;/: Cancer/NNP vaccine/NN adjuvant/JJ ;/: NS1/NN ;/: Poly/NNP -LRB-/-LRB- I/PRP :/: C/NN -RRB-/-RRB- ;/: TLR3/NN